PineTree Therapeutics (2)
- Founded: 2019
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: Oncology
- Drug types: ONC, INF
- Lead product: TAER-TAB platform
- Product link: https://www.pinetreetx.com/taer-tab.html
- Funding: $23.5M A1 Jun 2022
- Investors: InterVest, SK Securities, DSC Investment, J Curve Investment, Samho Green Investment, SJ Investment Partners
pinetreetx.com linkedin.com job board
Short description:
Antibody Therapy, Virus-Targeting Recombinant Agent
Drug notes:
ViTRAP platform RD infectious diseases
Long description:
PineTree Therapeutics is developing novel medicines to combat drug resistance in oncology. To overcome the shortcomings of existing therapies, PineTree is creating targeted protein degraders. This includes PineTree’s AbReptorTM, a transformative modular bi-specific and multi-specific antibody platform designed to degrade membrane-bound and extracellular proteins. AbReptor works by co-engaging a target protein, either surface-receptor or extracellular proteins with another proprietary receptor target. PineTree’s lead candidate, PTX-299, a bispecific antibody for EGFR-driven cancers is not in IND-enabling studies.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com